Amplified anticoagulant activity of tissue factor-targeted thrombomodulin

Summary

Tissue factor (TF) exposure isa potent pro-thrombotic trigger that initiates activation of the coagulation cascade, while thrombomodulin (TM) is a potent anticoagulant protein that limits the extent of activation. Both TF neutralizing antibodies and soluble TM (sTM) are effective anticoagulants. We have developed a novel anticoagulant fusion protein, Ab(TF)-TM, by fusing a TF-neutralizing single-chain antibody, Ab(TF), to an active fragment of TM. Ab(TF)-TM is a novel anticoagulant targeting to sites of TF exposure with a dual mechanism of action. The Ab(TF) portion of the molecule inhibits TF/factor VIIa mediated activation of FIX and FX, and the TM portion of the molecule acts as a cofactor for activation of protein C. In-vitro coagulation assays show that Ab(TF)-TM more potently inhibits TF-initiated coagulation (prothrombin time) than can its individual components, Ab(TF) (20-fold) and sTM (80-fold) alone, or in combination (10-fold). In contrast, the potency of Ab(TF)-TM in the activated partial thromboplastin and thrombin clotting time assays was similar to sTM alone. Ina rat model of disseminated intravascular coagulation (DIC), intravenous injection of a human TF-containing thromboplastin reagent (0.5 ml/kg) resulted in an immediate death in ∼60% of the animals and a clinical score of ∼2.5. Pre-injection of Ab(TF)-TM or Ab(TF) and sTM, given alone or in combination, showed dose-dependent efficacy. At a dose of 0.7 nmol/kg, Ab(TF)-TM completely prevented death and reduced clinical scores by 79%, while neither Ab(TF) nor sTM, given alone or in combination, showed significant therapeutic effects. Calculated effective doses that reduced mortality by 50% relative to that in the control group (ED₅₀, nmol/kg) were 0.21 for Ab(TF)-TM, 3.2 for an equimolar mixture of Ab(TF) and sTM, 4.3 for sTM and 20 for Ab(TF). Thus, Ab(TF)-TM presented 10– to 100-fold enhancement of the anticoagulant potency, relative to the ED₅₀ in Ab(TF) and sTM given either alone or in combination, in a rat DIC model.

Keywords

Tissue factor - thrombomodulin - fusion protein - anticoagulant - rat thromboembolism

• References

• 1 Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int J Hematol 2004; 79: 103-8.
• 2 Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995; 74: 180-4.
• 3 Bonderman D, Teml A, Jakowitsch J. et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002; 99: 2794-800.
• 4 McLean K, Schirm S, Johns A. et al. FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834. Thromb Res 2001; 103: 281-97.
• 5 Erlich JH, Boyle EM, Labriola J. et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000; 157: 1849-62.
• 6 Toschi V, Gallo R, Lettino M. et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
• 7 Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-30.
• 8 Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res 2001; 89: 1-2.
• 9 Himber J, Refino CJ, Burcklen L. et al. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb Haemost 2001; 85: 475-81.
• 10 Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. Faseb J 1995; 09: 946-55.
• 11 Esmon CT, Fukudome K. Cellular regulation of the proteinC pathway. Semin Cell Biol 1995; 06: 259-68.
• 12 Esmon CT. Inflammation and thrombosis: the impact of inflammation on the protein C anticoagulant pathway. Haematologica 1995; 80 (Suppl. 02) 49-56.
• 13 Esmon CT. Inflammation. They’re not just for clots anymore. Curr Biol 1995; 05: 743-6.
• 14 Esmon CT. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Clin Haematol 1994; 07: 453-68.
• 15 Lane DA, Kunz G, Olds RJ. et al. Molecular genetics of antithrombin deficiency. Blood Rev 1996; 10: 59-74.
• 16 Lane DA, Mannucci PM, Bauer KA. et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-62.
• 17 Lane DA, Mannucci PM, Bauer KA. et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996; 76: 824-34.
• 18 Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49: 5-7.
• 19 Taylor Jr. FB, Chang A, Ruf W. et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-34.
• 20 Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 718-21.
• 21 McLean K, Masikat MR, Rumennik G. et al. Tissue factor targeted thrombomodulin (Ab(TF)-TM) – a novel tissue factor neutralizing antibody fused to thrombomodulin (TM). J Thromb Haemost 2005; 03 (Suppl. 01) P1359.
• 22 Nemerson Y, Gentry R. An ordered addition, essential activation model of the tissue factor pathway of coagulation: evidence for a conformational cage. Biochemistry 1986; 25: 4020-33.
• 23 Zaman AG, Helft G, Worthley SG. et al. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000; 149: 251-66.
• 24 Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 09: 2752-5.
• 25 Brand K, Fowler BJ, Edgington TS. et al. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Biol 1991; 11: 4732-8.
• 26 Chou J, Mackman N, Merrill-Skoloff G. et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-7.
• 27 Rauch U, Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 2000; 10: 139-43.
• 28 Bogdanov VY, Balasubramanian V, Hathcock J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 09: 458-62.
• 29 Harker LA, Hanson SR, Kelly AB. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995; 74: 464-72.
• 30 Levy MM, Fink MP, Marshall JC. et al. 2001 SCCM/ ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-8.
• 31 Angus DC, Linde-Zwirble WT, Lidicker J. et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
• 32 Zisman DA, Kunkel SL, Strieter RM. et al. Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis. Shock 1997; 08: 349-56.
• 33 Zisman DA, Kunkel SL, Strieter RM. et al. MCP-1 protects mice in lethal endotoxemia. J Clin Invest 1997; 99: 2832-6.
• 34 Bernard GR, Ely EW, Wright TJ. et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29: 2051-9.
• 35 Abendschein D, Wang Y-X, Light D. et al. Inhibition of thrombosis after vascular injury with a novel tissue factor-targeted thrombomodulin fusion protein. J Thromb Haemost 2005; 03 (Suppl. 01) OR077.